Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Receivables (2024 - 2025)

Stoke Therapeutics (STOK) has 2 years of Receivables data on record, last reported at $10.8 million in Q3 2025.

  • For Q3 2025, Receivables changed N/A year-over-year to $10.8 million; the TTM value through Sep 2025 reached $10.8 million, changed N/A, while the annual FY2024 figure was $2.4 million, N/A changed from the prior year.
  • Receivables reached $10.8 million in Q3 2025 per STOK's latest filing, up from $2.4 million in the prior quarter.
  • Across five years, Receivables topped out at $10.8 million in Q3 2025 and bottomed at $2.4 million in Q4 2024.